BH.IMMUN&BIO | KOPRAN. | BH.IMMUN&BIO/ KOPRAN. |
|||
---|---|---|---|---|---|
P/E (TTM) | x | -7.7 | 30.3 | - | View Chart |
P/BV | x | 1.5 | 2.8 | 54.1% | View Chart |
Dividend Yield | % | 0.0 | 1.2 | - |
BH.IMMUN&BIO KOPRAN. |
EQUITY SHARE DATA | |||||
---|---|---|---|---|---|
BH.IMMUN&BIO Mar-23 |
KOPRAN. Mar-23 |
BH.IMMUN&BIO/ KOPRAN. |
5-Yr Chart Click to enlarge
|
||
High | Rs | 52 | 327 | 15.8% | |
Low | Rs | 21 | 96 | 21.4% | |
Sales per share (Unadj.) | Rs | 10.3 | 114.3 | 9.0% | |
Earnings per share (Unadj.) | Rs | -3.9 | 5.6 | -68.2% | |
Cash flow per share (Unadj.) | Rs | -3.8 | 8.3 | -45.9% | |
Dividends per share (Unadj.) | Rs | 0 | 3.00 | 0.0% | |
Avg Dividend yield | % | 0 | 1.4 | 0.0% | |
Book value per share (Unadj.) | Rs | 20.4 | 91.1 | 22.4% | |
Shares outstanding (eoy) | m | 43.18 | 48.21 | 89.6% | |
Bonus / Rights / Conversions | 0 | 0 | - | ||
Price / Sales ratio | x | 3.5 | 1.9 | 188.9% | |
Avg P/E ratio | x | -9.4 | 37.5 | -25.0% | |
P/CF ratio (eoy) | x | -9.5 | 25.5 | -37.2% | |
Price / Book Value ratio | x | 1.8 | 2.3 | 76.2% | |
Dividend payout | % | 0 | 53.1 | -0.0% | |
Avg Mkt Cap | Rs m | 1,561 | 10,205 | 15.3% | |
No. of employees | `000 | NA | NA | - | |
Total wages/salary | Rs m | 151 | 499 | 30.3% | |
Avg. sales/employee | Rs Th | 0 | 0 | - | |
Avg. wages/employee | Rs Th | 0 | 0 | - | |
Avg. net profit/employee | Rs Th | 0 | 0 | - |
INCOME DATA | |||||
---|---|---|---|---|---|
Net Sales | Rs m | 446 | 5,510 | 8.1% | |
Other income | Rs m | 11 | 31 | 34.6% | |
Total revenues | Rs m | 457 | 5,541 | 8.2% | |
Gross profit | Rs m | -161 | 518 | -31.0% | |
Depreciation | Rs m | 2 | 127 | 1.6% | |
Interest | Rs m | 71 | 61 | 116.1% | |
Profit before tax | Rs m | -223 | 361 | -61.7% | |
Minority Interest | Rs m | 0 | 0 | - | |
Prior Period Items | Rs m | 0 | 0 | - | |
Extraordinary Inc (Exp) | Rs m | 0 | 0 | - | |
Tax | Rs m | -56 | 88 | -63.7% | |
Profit after tax | Rs m | -166 | 272 | -61.1% | |
Gross profit margin | % | -36.0 | 9.4 | -383.2% | |
Effective tax rate | % | 25.3 | 24.5 | 103.2% | |
Net profit margin | % | -37.3 | 4.9 | -754.6% |
BALANCE SHEET DATA | |||||
---|---|---|---|---|---|
Current assets | Rs m | 358 | 3,991 | 9.0% | |
Current liabilities | Rs m | 940 | 1,770 | 53.1% | |
Net working cap to sales | % | -130.6 | 40.3 | -323.9% | |
Current ratio | x | 0.4 | 2.3 | 16.9% | |
Inventory Days | Days | 85 | 11 | 803.1% | |
Debtors Days | Days | 1,135 | 1,077 | 105.4% | |
Net fixed assets | Rs m | 1,262 | 2,506 | 50.3% | |
Share capital | Rs m | 432 | 482 | 89.6% | |
"Free" reserves | Rs m | 450 | 3,910 | 11.5% | |
Net worth | Rs m | 882 | 4,392 | 20.1% | |
Long term debt | Rs m | 0 | 179 | 0.0% | |
Total assets | Rs m | 1,620 | 6,497 | 24.9% | |
Interest coverage | x | -2.2 | 6.9 | -31.1% | |
Debt to equity ratio | x | 0 | 0 | 0.0% | |
Sales to assets ratio | x | 0.3 | 0.8 | 32.5% | |
Return on assets | % | -5.9 | 5.1 | -115.3% | |
Return on equity | % | -18.9 | 6.2 | -304.2% | |
Return on capital | % | -17.2 | 9.2 | -187.0% | |
Exports to sales | % | 0 | 44.7 | 0.0% | |
Imports to sales | % | 14.5 | 10.1 | 142.9% | |
Exports (fob) | Rs m | NA | 2,464 | 0.0% | |
Imports (cif) | Rs m | 65 | 558 | 11.6% | |
Fx inflow | Rs m | 0 | 2,464 | 0.0% | |
Fx outflow | Rs m | 65 | 624 | 10.3% | |
Net fx | Rs m | -65 | 1,840 | -3.5% |
CASH FLOW | |||||
---|---|---|---|---|---|
From Operations | Rs m | 109 | 340 | 32.0% | |
From Investments | Rs m | 5 | -127 | -3.7% | |
From Financial Activity | Rs m | -147 | -198 | 74.1% | |
Net Cashflow | Rs m | -34 | 15 | -219.7% |
Indian Promoters | % | 59.3 | 44.5 | 133.2% | |
Foreign collaborators | % | 0.0 | 0.0 | - | |
Indian inst/Mut Fund | % | 0.0 | 2.0 | - | |
FIIs | % | 0.0 | 0.8 | - | |
ADR/GDR | % | 0.0 | 0.0 | - | |
Free float | % | 40.8 | 55.5 | 73.4% | |
Shareholders | 35,313 | 50,850 | 69.4% | ||
Pledged promoter(s) holding | % | 0.0 | 0.0 | - |
Compare BH.IMMUN&BIO With: DIVIS LABORATORIES CIPLA SUN PHARMA DR. REDDYS LAB ZYDUS LIFESCIENCES
No comparison is complete without understanding how the stock prices have performed over a period of time.
Here's a brief comparison:
Period | BH.IMMUN&BIO | KOPRAN. | S&P BSE HEALTHCARE |
---|---|---|---|
1-Day | -2.23% | -2.80% | 0.31% |
1-Month | -2.23% | -6.47% | 0.08% |
1-Year | 28.97% | 65.64% | 54.11% |
3-Year CAGR | -13.27% | 10.88% | 14.46% |
5-Year CAGR | 30.36% | 45.79% | 20.04% |
* Compound Annual Growth Rate
Here are more details on the BH.IMMUN&BIO share price and the KOPRAN. share price.
Moving on to shareholding structures...
The promoters of BH.IMMUN&BIO hold a 59.3% stake in the company. In case of KOPRAN. the stake stands at 44.5%.
To review how promoter stakes have changed over time, and how much of the promoter stake is pledged, please see the shareholding pattern of BH.IMMUN&BIO and the shareholding pattern of KOPRAN..
Finally, a word on dividends...
In the most recent financial year, BH.IMMUN&BIO paid a dividend of Rs 0.0 per share. This amounted to a Dividend Payout ratio of -0.0%.
KOPRAN. paid Rs 3.0, and its dividend payout ratio stood at 53.1%.
You may visit here to review the dividend history of BH.IMMUN&BIO, and the dividend history of KOPRAN..
For a sector overview, read our pharmaceuticals sector report.
After opening the day on positive note, Indian share markets continued the momentum as the session progressed and ended higher.